Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index; 127 of the 159 sources its claims cite were checked for support.

Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance

Open access

Abstract

Review of antifungal heteroresistance as a reversible minority subpopulation phenomenon distinct from tolerance and persistence, with clinical implications for survival and treatment failure.

Overview

CoChat Summary

TL;DR

Antifungal heteroresistance is a reversible, often inducible phenotype in which a minority resistant fungal subpopulation coexists with a susceptible majority, complicating susceptibility testing and treatment. This narrative review summarizes known mechanisms—especially aneuploidy/copy number variation and gene-expression changes—and clinical implications, while noting that fungal heteroresistance remains underexplored compared with bacterial heteroresistance.

Key findings

  • Heteroresistance can involve resistant subpopulations as rare as one in one million cells and may cause treatment failure, breakthrough infection, relapse, or prophylaxis failure despite in vitro susceptibility.
  • Aneuploidy and copy number variations are central mechanisms, with examples including chr5/ERG11/TAC1 in *C. albicans*, chrE in *N. glabrata*, chr1 disomy in *C. neoformans*, and cross-resistance to azoles and 5-FC after fluconazole exposure.
  • Clinical impact is substantial: invasive fungal infection mortality ranges from 40% to 70% in candidiasis, 40% to 80% in cryptococcosis, and can exceed 90% in aspergillosis; untreated high-level heteroresistant brain-infected mice reached 100% 20-day mortality.
  • Conventional MIC-based testing may miss heteroresistant subpopulations; population analysis profile (PAP) is recommended as the gold standard, with time-kill and single-cell assays as additional approaches. No approved first-line therapies exist, though combination therapy or dose escalation may help, and adding 5-FC or amphotericin B to fluconazole monotherapy has achieved up to 90% efficacy in some settings.

Methods

  • Narrative review of antifungal heteroresistance, tolerance, and persistence, synthesizing mechanisms and clinical relevance.
  • Literature identified through PubMed and Web of Science using keywords “antifungal heteroresistance,” “antifungal resistance,” “antifungal tolerance,” and “antifungal persistence”; articles from 1995 to 2025 were considered.
  • Priority given to peer-reviewed research articles, reviews, and case reports relevant to clinical microbiology and antifungal therapy; non-English articles, conference abstracts, and studies with ambiguous definitions or lacking direct relevance were excluded.

Limitations

  • Stated: fungal heteroresistance remains largely underexplored, most research focuses on azole resistance, clinically important mechanisms have not been studied in sufficient depth, and comparative studies and clinical trials remain limited.
  • Stated: mechanisms of stress induction and the genes involved in some heteroresistance phenotypes need further exploration.
  • Evident from the text: as a narrative review, it does not provide a systematic quantitative synthesis or meta-analysis, and it notes ongoing definitional overlap between heteroresistance, tolerance, and persistence in the literature.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/jof11020143

Cites

184 of 184 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Antifungal mode of action of azoles, AMB, 5-FC and echinocandins. Azoles inhibit ergosterol biosynthesis by targeting sterol 14α-demethylase, producing toxic 14-methyl sterols, altering fungal cell membrane permeability and metabolic state [74,75]. Echinocandins target β-1,3-glucan synthase, impairing fungal cell wall integrity and stress resistance [76]. Amphotericin B binds to membrane ergosterol, forming pores that disrupt permeability and cause reactive oxygen species (ROS) accumulation, leading to cell death [77,78,79]. 5-FC is converted intracellularly to 5-FU, inhibiting DNA and RNA synthesis [80,81].
Figure 1 Antifungal mode of action of azoles, AMB, 5-FC and echinocandins. Azoles inhibit ergosterol biosynthesis by targeting sterol 14α-demethylase, producing toxic 14-methyl sterols, altering fungal cell membrane permeability and metabolic state [74,75]. Echinocandins target β-1,3-glucan synthase, impairing fungal cell wall integrity and stress resistance [76]. Amphotericin B binds to membrane ergosterol, forming pores that disrupt permeability and cause reactive oxygen species (ROS) accumulation, leading to cell death [77,78,79]. 5-FC is converted intracellularly to 5-FU, inhibiting DNA and RNA synthesis [80,81].CC BY · PubMed Central
Figure 2 (By Figdraw 2.0). Explanation of resistance, susceptible, tolerance, persistence and heteroresistance from a cell population perspective. The state of cell proliferation is represented by the number of cells in the figure. Individual colors indicate different genotypes and phenotypes, which are red (genetically stable resistant), blue (susceptible), yellow (genetically unstable or phenotypically resistant), green (phenotypically tolerant).
Figure 2 (By Figdraw 2.0). Explanation of resistance, susceptible, tolerance, persistence and heteroresistance from a cell population perspective. The state of cell proliferation is represented by the number of cells in the figure. Individual colors indicate different genotypes and phenotypes, which are red (genetically stable resistant), blue (susceptible), yellow (genetically unstable or phenotypically resistant), green (phenotypically tolerant).CC BY · PubMed Central

Verification

Claims the paper makes

90 Valid · 4 Not valid · 14 Not checked · 28 Own results and interpretations

86 more claims · 62 with their cited sources checked

Create a free account to see all 136 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 41
  • Probably not a substantial claim. 10

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 180 references

Cited by

See all 18

Metadata

Authors
Su, Y., Li, Y., Yi, Q., Xu, Y., Sun, T., & Li, Y.
Affiliations
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
  • Sun, Tianshu
  • Li, Yingxing
Venue
Journal of Fungi
Publisher
MDPI AG
Published
2025-02-13
Volume
11
Issue
2
Pages
143
ISSN
2309-608X (ISSN-L)
OpenAlex
W4407526169
Cited by
18
References
180
Citations by year
2026: 12 · 2025: 6
FWCI
3.13
Type
journal article
Language
en
Open access
Locations
  • Journal of Fungi (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National High Level Hospital Clinical Research Funding (2022-PUMCH-C-052)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords
antifungal resistance, fungal pathogens, drug tolerance, fungal persistence, susceptibility testing, treatment failure, recurrent fungal infection, immunocompromised patients, antifungal therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance. https://app.cochat.ai/papers/10.3390/jof11020143
The paper
Su, Y., Li, Y., Yi, Q., Xu, Y., Sun, T., & Li, Y. (2025). Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance. Journal of Fungi. https://doi.org/10.3390/jof11020143

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.